CEROW — CERO THERAPEUTICS HOLDINGS, INC.

—
OTC · Health Care · Biotechnology · CIK 1870404 ·
Last close
$0.00
Market Cap
—
52W High
$0.00
52W Low
$0.00
ADV30
78,000
Next earnings
—
CERo Therapeutics Holdings, Inc., an immunotherapy company, engages in the development of engineered T cell therapeutics for the treatment of cancer. The company's lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 0 — -3,846,466 -1,028,830 1,899,971 937,512 32,405,268
Mar 2026 0 — -4,845,728 -5,885,914 2,205,110 857,489 11,463,865
Dec 2025 0 — -4,426,248 -4,540,621 3,641,134 1,662,380 9,087,596
Sep 2025 0 — -4,362,579 -4,856,395 3,911,394 2,022,072 8,454,556

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-12,100,507
Investing CF
$0
Financing CF
$9,235,345
CapEx
—
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
—
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-97,752,859
Inventory
—
Receivables
—
ST Investments
$500,000
EBIT TTM
$-14,847,241
Pretax Income TTM
$-16,311,760
Interest Exp TTM
$856,330
Analysts
—

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -19,326,699 -19,920,262 3,641,134 9,087,596 -5,446,462 -16,080,250
Dec 2024 — — — 6,206,929 8,101,492 -1,894,563 —
Dec 2023 0 -7,675,049 -7,289,577 5,126,302 47,183,997 -42,057,695 -5,789,987
Dec 2022 0 -11,971,231 -11,829,116 11,349,488 46,220,268 -34,870,780 -11,709,311
Dec 2021 0 -11,616,331 -10,629,620 — — — -10,094,380

TTM Snapshot

Revenues TTM
—
NetIncome TTM
$-16,311,760
OpCashFlow TTM
—
Assets (Latest)
$1,899,971
Forward EPS
—

Peers — same industry

TickerNameMarket CapLastDaily %
AMGN AMGEN INC $247.70B $457.93 —
GILD GILEAD SCIENCES, INC. $211.18B $170.26 —
MRNA Moderna, Inc. $82.56B $206.80 —
ARGX ARGENX SE $58.92B $947.52 —
BIIB BIOGEN INC. $37.07B $250.79 —

News headlines (Yahoo Finance, 1h cache)

CERo Therapeutics Doses Third Patient in Cohort 2 of Phase 1 CER-1236 Trial
2026-04-14 12:15 · Yahoo
CERo Therapeutics Doses 7th Patient in Phase 1 CER-1236 Trial
2026-11-03 13:15 · Yahoo
CERo Therapeutics Announces Activation of the University of California, Davis as a Clinical Trial Site for the Ongoing Phase 1 CERTAIN-T Trial of CER-1236 in Hematologic Malignancies
2026-10-26 21:21 · Yahoo
SRX Global Announces Activation of the University of California, Davis as a Clinical Trial Site for CERo Therapeutics’ Ongoing Phase 1 CERTAIN-T Trial of CER-1236 in Hematologic Malignancies
2026-10-26 13:05 · Yahoo
CERo Therapeutics Announces Activation of Additional Clinical Trial Site for the CERTAIN-T Trial, its Ongoing Phase 1 Clinical Trial of CER-1236 in Hematological Cancers
2026-10-26 13:00 · Yahoo
SRX Global and CERO 1236, a Wholly-Owned SPV, Enter into Definitive Agreement to Acquire CERo Therapeutics, an Innovative Cellular Immunotherapy Company Developing CER 1236 for Hematologic Malignancie
2026-10-07 19:00 · Yahoo
SRX Global Acquires Senior Secured Debt in CERo Therapeutics Holdings, Inc., an Innovative Cellular Immunotherapy Company with Cancer Fighting Molecule for the Treatment of Hematologic Cancers
2026-08-31 11:30 · Yahoo
CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors
2026-02-17 13:00 · Yahoo
CERo Therapeutics to Present Late-Breaking Oral Poster Session Highlighting Interim Phase 1 Data from CERTAIN-T Trial Highlighting Platelet Transfusion Independence in a High-Risk MDS/AML Patient
2026-02-04 14:05 · Yahoo
CERo Therapeutics Provides Clinical Update on Phase 1 Trial of CER-1236 in AML (CertainT-1) Highlighting Key Safety Data and Platelet Transfusion–Free Interval Observed in a Patient with Myelodysplas
2026-01-07 14:09 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.